Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $22.00.
Several equities research analysts have weighed in on IMUX shares. Wedbush reiterated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a report on Tuesday, January 31st. StockNews.com initiated coverage on Immunic in a report on Thursday, March 16th. They issued a “sell” rating for the company.
Institutional Investors Weigh In On Immunic
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC purchased a new stake in shares of Immunic during the 1st quarter valued at approximately $134,000. JPMorgan Chase & Co. raised its position in shares of Immunic by 21.2% during the 1st quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company’s stock valued at $154,000 after buying an additional 2,387 shares during the period. Rhumbline Advisers raised its position in shares of Immunic by 30.6% during the 1st quarter. Rhumbline Advisers now owns 22,122 shares of the company’s stock valued at $250,000 after buying an additional 5,182 shares during the period. Marshall Wace LLP acquired a new position in Immunic during the third quarter worth $77,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Immunic during the third quarter worth $80,000. 60.67% of the stock is owned by institutional investors and hedge funds.
Immunic Price Performance
Immunic (NASDAQ:IMUX – Get Rating) last announced its earnings results on Thursday, February 23rd. The company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.81). As a group, equities analysts expect that Immunic will post -2.03 EPS for the current fiscal year.
Immunic Company Profile
Immunic, Inc is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856.
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.